Stock Analysis
Novavax IncNVAX
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsBuy15 analystsPrice is 76% of the way from the year's low to its high.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation40
- Growth0
Weak fundamentals at a demanding price.
Market context
-12.2% today· Z 2.4σ
What's happening with NVAX
Profile
growth, profitability, moat, earnings quality, financial health and valuation lag behind.
How is each axis scored?
- Valuation40/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-2.3%)0/25
- P/S (4.4x)20/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-0.5%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-59.9%)0/25
- Operating margin (-56.6%)0/25
- Financial Health28/100 · Weak
- Altman Z (-1.66)3/25
- Current ratio (2.13)25/25
- Interest coverage (-35.2x)0/25
- Net cash / debt (n/a)0/25
- Quality15/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (0.22)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 596.8%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (-117.4%)0/25
- FCF-positive years (1/10 yrs)0/25
- Worst-year net margin (worst -1823.5%)0/25
Risk Flags
- ⚠Altman Z -1.7 — distress-zone balance sheet
- ⚠Beneish M 0.22 — earnings-manipulation flag
- ⚠Negative FCF margin (-0.1%) — burning cash
- ⚠SBC 7.8% of revenue — real dilution cost
- ⚠9 loss-making years in recent history
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. Show more
The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Headquarters: GAITHERSBURG, MD · Employees: 749 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
40D+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF19.7xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-2.3%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -160.5%–8.7% · 70th pct
P/S (TTM)4.45xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 0.2x–16.0x · 89th pct
EV/EBITDA4.9xA
Grade A: CheapEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales5.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-22.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-59.9%D
Grade D: LowNet Income / Revenue
Operating Margin-56.6%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin78.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-10.3%D
Grade D: LowFCF / Revenue
True FCF Margin-18.1%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-0.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+124.2%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue7.8%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
28EAltman Z-Score-1.66D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.13xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.23xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-35.2xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
15EPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score0.22D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability596.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.38xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 records| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Rodgers Richard J Filed | Rodgers Richard J | Option exercise | -18880 | |
Rodgers Richard J Filed | Rodgers Richard J | Option exercise | +18.9K | |
King Rachel K. Filed | King Rachel K. | Option exercise | -18880 | |
King Rachel K. Filed | King Rachel K. | Option exercise | +18.9K | |
DOUGLAS RICHARD Filed | DOUGLAS RICHARD | Option exercise | -18880 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
DOUGLAS RICHARD Filed | DOUGLAS RICHARD | Option exercise | +18.9K | |
MCGLYNN MARGARET G Filed | MCGLYNN MARGARET G | Option exercise | -18880 | |
MCGLYNN MARGARET G Filed | MCGLYNN MARGARET G | Option exercise | +18.9K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)-117.4%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-1823.5%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.36
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.23
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$735.13M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-127.75M
Shareholders' equity (book value)
Asset / Liability0.90xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$1.84B
Current Market Capitalization
Beta2.81D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Novavax Inc (NVAX)
NVAX is down 12.17% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Novavax Inc. Altman Z-Score of -1.66 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of 0.22 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny.
- Revenue has been contracting (CAGR ≈ -1%), which weighs on the growth outlook.
- Free-cash-flow margin is negative (-10%) — the business currently burns cash.
- Interest coverage of -35.2× leaves little room for earnings shocks.
- Novavax Inc posted a net loss in 9 of 10 available completed fiscal years (2016–2025).
See how NVAX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NVAX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 11.23 | -12.44% | -2.33 |
| Oct 16 | After-hours | 11.15 | -13.03% | -2.43 |
| Oct 9 | Regular | 12.98 | +17.89% | 2.77 |
| Oct 9 | After-hours | 12.73 | +15.62% | 2.42 |
| Oct 6 | Regular | 11.04 | -12.10% | -2.68 |
Frequently Asked Questions about NVAX
What is the current Novavax Inc (NVAX) stock price?
NVAX is trading at $11.26 at the last market close, down 12.17% on the session. PreMarketPrice tracks NVAX pre-market, intraday and after-hours prices.
Is NVAX stock a buy right now?
PreMarketPrice's quantitative model rates Novavax Inc's financial health at 28/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NVAX stock overvalued?
Novavax Inc trades at a trailing P/E of n/a and our valuation score rates it 40/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Novavax Inc report earnings?
No confirmed earnings date is currently scheduled for NVAX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Novavax Inc operate in?
Novavax Inc operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Novavax Inc do?
Novavax Inc is a biotechnology company that develops vaccines.
About Novavax Inc (NVAX) Stock
Novavax Inc (NVAX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Novavax Inc is trading at $11.26, down 12.17% on the day with a market capitalization of $1.8 billion. The financial health score for NVAX is 28/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NVAX stock.
NVAX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Novavax Inc (NVAX) across multiple dimensions:
- Pre-market price & movement: Real-time NVAX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NVAX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Novavax Inc across multiple reporting periods.
- Financial health score: A composite score of 28/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NVAX.
- Sector peers: Compare NVAX against 5 other healthcare stocks on key financial metrics.
Is NVAX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Novavax Inc (NVAX) as an investment. The financial health score of 28/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Novavax Inc (NVAX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.